Hani Zamil, MD
Gastroenterology · Houston, TXNPI 1346430477
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Medical Device Business Services, Inc. accounts for 63.0% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $16,835 and has fallen 93.6% since, to $1,070 in 2025. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $101.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$23K
- Medtronic$6K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$939
- Merck$512
- plus $3K from 28 others
Across 1 payment — averaging $1300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Consulting fees$20,46157%
- Speaking & faculty fees$4,74013%
- Travel & lodging$2,5667%
- Food & beverage$8,02922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 27 | $22,542 |
| Medtronic | 11 | $5,762 |
| Johnson & Johnson(2 entities) | 43 | $1,842 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 64 | $1,020 |
| AbbVie | 54 | $939 |
| Merck | 22 | $512 |
| QOL Medical, LLC | 21 | $403 |
| Olympus Corporation Of The Americas | 4 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $294 |
| Ironwood Pharmaceuticals, Inc | 16 | $275 |
| Regeneron Healthcare Solutions, Inc. | 7 | $195 |
| Sanofi | 7 | $185 |
| Covidien LP | 2 | $181 |
| Nestle Healthcare Nutrition Inc. | 10 | $180 |
| Boston Scientific | 1 | $119 |
| Evoke Pharma, Inc. | 6 | $103 |
| Aimmune Therapeutics, Inc. | 6 | $100 |
| Bristol Myers Squibb | 6 | $98 |
| Aries Pharmaceuticals, Inc. | 1 | $90 |
| Braintree Laboratories, Inc. | 6 | $88 |
| Vivus LLC | 4 | $77 |
| Ardelyx, Inc. | 3 | $77 |
| Ferring Pharmaceuticals Inc. | 4 | $62 |
| Madrigal Pharmaceuticals | 3 | $57 |
| Lumendi LLC | 1 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| AstraZeneca(2 entities) | 2 | $36 |
| Olympus America Inc. | 2 | $28 |
| Ambu Inc. | 2 | $27 |
| Gilead | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,796 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 16 | $43,715 |
| LinzessLinaclotide | 28 | $29,807 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 49 | $3,057 |
| Sucralfate | 30 | $2,962 |
| Pantoprazole Sodium | 212 | $2,192 |
| Famotidine | 102 | $1,392 |
| Ursodiol | 13 | $1,252 |
| Omeprazole | 88 | $691 |
| Esomeprazole Magnesium | 19 | $619 |
| Baclofen | 20 | $325 |
| Ondansetron OdtOndansetron | 15 | $280 |
| Dicyclomine Hcl | 25 | $205 |
| Ondansetron Hcl | 14 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,020 | $43,71516 claims |
| AbbVieLinzess | $939 | $29,80728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.